atorvastatin / Generic mfg. - LARVOL DELTA

FDA Drug Repurposing Uncovers Modulators of Dopamine D2 Receptor Localization via Disruption of the NCS-1 Interaction. (PubMed, J Med Chem) - "Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism."

Journal • DRD2 • NCS1

Abnormal autophagy is a critical mechanism in TANGO2-related rhabdomyolysis (SSIEM 2023) - "In zebrafish larvae, tango2 knockdown induces locomotor defects characterized by reduced evoked movements which are exacerbated by exposure to atorvastatin, a compound known to cause RM... Overall, we demonstrate that TANGO2 plays an important role in autophagy, the efficiency of which is critical to prevent RM."

High-Dose Atorvastatin Doesn't Alter Fitness or Skeletal Muscle Mitochondria in Adults With Obesity (OBESITY WEEK 2025) - "This double-blinded RCT found limited effect of low- or high-dose atorvastatin therapy on fasting glucose, cardiorespiratory fitness, or skeletal muscle respiratory function after twelve months in participants with obesity at risk for CVD."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Musculoskeletal Pain • Obesity • Type 2 Diabetes Mellitus

FIB-4 & MASLD: An Underused Scorecard for Cardiovascular Disease Prevention (OBESITY WEEK 2025) - "Medications included Atorvastatin 40 mg, Aspirin 81 mg, Metformin 2000 mg, and Jardiance 15 mg...The patient was counseled on diet and exercise, and initiated on incretin therapy with a subsequent decrease of his liver enzymes to normal by September 2024 following 1-year of incretin therapy (Ozempic, then Mounjaro)... With the increasing prevalence of CVD, enhanced risk stratification is essential for identifying high-risk populations. More importantly, acknowledging the strong connection between liver health and cardiovascular outcomes could inspire more integrated approaches to primary and secondary prevention, ultimately improving population health and alleviating the healthcare burden associated with heart disease. Future research should prioritize incorporating FIB-4 screening into CVD risk assessment models, enabling more targeted preventive strategies for high-risk populations."

Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Heart Failure • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Solid Tumor • Type 2 Diabetes Mellitus

Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. (PubMed, JAMA Cardiol) - P2 | "Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy. ClinicalTrials.gov Identifier: NCT02943590."

Clinical • Journal • Cardiovascular • Hematological Malignancies • Lymphoma • Oncology

Statin-Associated Immune-Mediated Necrotizing Myopathy With Dual Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (Anti-HMGCR) and Anti-OJ Positivity: A Case Report of Fulminant Weakness and Respiratory Failure. (PubMed, Cureus) - "He was on Atorvastatin for elevated cholesterol levels...With intensive multidisciplinary care, including respiratory, rheumatology, physiotherapy, and speech therapy, he gradually improved in respiratory function and mobility, regaining upper limb strength and partial independence at discharge.  This case demonstrates the diagnostic complexity of IMNM, the need for early recognition in patients with statin exposure and rapidly progressive weakness, and the importance of aggressive immunosuppression alongside comprehensive multidisciplinary care. Despite multiple complications, meaningful functional recovery is possible with timely and coordinated management."

Journal • Asthma • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Gastrointestinal Disorder • Immunology • Infectious Disease • Metabolic Disorders • Myositis • Nephrology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Type 2 Diabetes Mellitus

Association Between Statin Use And Asthma Exacerbations In Patients With Ischemic Heart Disease And Asthma (ACAAI 2025) - "Patients prescribed atorvastatin, rosuvastatin, or simvastatin comprised the statin group. However, among those who experienced at least one exacerbation, the mean number per patient did not differ significantly between groups ( p = 0.59), suggesting the association is driven by event occurrence rather than severity. Conclusion Statin use was associated with a modest but statistically significant increase in asthma exacerbations among patients with IHD and asthma."

Clinical • Asthma • Cardiovascular • Coronary Artery Disease • Heart Failure • Immunology • Inflammation • Respiratory Diseases

DRESS Syndrome: A Rare Atorvastatin-Triggered Case. (ACAAI 2025) - "Intravenous Methylprednisolone (1 mg/kg/day) was initiated. DRESS, if undiagnosed and untreated early, can progress to severe organ damage and death. Thus, early intervention with steroids and immunomodulators can dramatically reverse potential poor outcomes."

Clinical • Cardiovascular • Eosinophilia • Fatigue • Hepatology • Immunology • Infectious Disease • Liver Failure • Septic Shock

Atorvastatin improves spermatogenesis in murine and in vitro human chronic orchitis models through restoring blood-testis barriers. (PubMed, Cell Death Discov) - "More importantly, atorvastatin also re-established the expression of BTB-associated proteins and increased the germ cell numbers in cultured human testis tissues. Collectively, our study reveals the essential impact of atorvastatin in improving spermatogenesis in murine and human chronic orchitis models through restoring BTB and suggests that atorvastatin as a promising agent for the clinical treatment of chronic orchitis."

Journal • Preclinical • Immunology • Infectious Disease

RECURRENT MYOCARDIAL INFARCTIONS IN THE SETTING OF PONATINIB THERAPY: A CARDIO-ONCOLOGY DILEMMA (CHEST 2025) - "With the diagnosis of Non-ST Elevation Myocardial Infarction, he was started on heparin infusion and continued on aspirin, ticagrelor, and atorvastatin 80 mg. Ponatinib is associated with a significant risk of cardiovascular adverse effects, particularly in patients with preexisting CAD. This case demonstrates the rare and rapid progression of ISR in such patients and emphasizes the importance of individualized treatment plans and aggressive cardiovascular risk factor optimization."

Cardiovascular • Chronic Myeloid Leukemia • Coronary Artery Disease • Hematological Malignancies • Leukemia • Myocardial Infarction • ABL1 • BCR

Identifying metabolic vulnerabilities of recurrent IDH1-R132H mutant glioma by high throughput screening (WFNOS 2025) - "Notable target pathways include folate metabolism and de novo thymidylate synthesis (methotrexate, raltitrexed, 5-FU), p97 AAA ATPase/VCP chaperone (CB-5083, ML240, eeyarestatin I), mevalonate pathway (Ro 48-8071 fumarate, atorvastatin calcium), and the BCL-2 family (Navitoclax, ABT-737). We are validating these drugs across a panel of patient-derived IDH-mutant gliomasphere models, and examining the combinatorial effects of these agents with vorasidenib and CDK4/6 inhibitors. Our results provide insight into important metabolic pathway dependencies in recurrent IDH1-R132H mutant gliomas that have targeting potential."

IO biomarker • Brain Cancer • Glioma • Oligodendroglioma • Solid Tumor • BCL2 • IDH1 • NAMPT

Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice. (PubMed, Biomed Pharmacother) - "In apoE-/- mice, bempedoic acid positively impacts plaque burden while preventing skeletal muscle mitochondrial dysfunction."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOE

Effects of dengue virus type-2 serotype (DENV-2) on the expression profile of matrix metalloproteinases in THP-1, monocyte cells and their roles in endothelial dysfunctions: protective effect of atorvastatin. (PubMed, Front Cell Infect Microbiol) - "Additionally, our finding shows that atorvastatin has MMPs' inhibitory potential against dengue, which may be adopted in clinical trials against severe dengue viral disease. The current findings are interesting; however, further studies may be needed to adopt the current findings in the future."

Journal • Dengue Fever • Infectious Disease • MMP14 • MMP2 • MMP9

Are statins a promising therapeutic strategy for macular edema? Insights from a systematic review and meta-analysis. (PubMed, Int J Retina Vitreous) - "Statins demonstrate promising anatomical and preventive benefits in diabetic macular edema, particularly in patients with dyslipidemia, by reducing lipid exudation and stabilizing retinal vasculature. Despite limited visual acuity improvement, their favorable safety profile supports considering statins as adjunctive therapy. Further large-scale, long-term trials are warranted to confirm these findings and optimize treatment protocols."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Dyslipidemia • Inflammation • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms (ASH 2025) - "Among patients on statins, a subgroup analysis wasperformed to assess the effect of high-intensity statin use (rosuvastatin ≥ 20 mg or atorvastatin ≥ 40 mg)compared with low or medium intensity statins... In patients with MPNs, statin use was associated with a reduced risk of arterial thrombosisand heart failure hospitalization, but not with hematologic progression or all-cause mortality. Notably, theintensity of statin therapy did not correlate with clinical outcomes among statin-treated patients. Thesefindings suggest that statins may provide meaningful cardiovascular protection in individuals with MPN,yet appear to be underutilized even among those with established clinical indications."

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Essential Thrombocythemia • Heart Failure • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • Thrombosis • CALR • JAK2

Lysophosphatidylcholine-induced macrophage polarization imbalance and functional dysregulation in immune thrombocytopenia (ASH 2025) - "In this study, we investigated whether LPCmodulates macrophage polarization and function in ITP patients via metabolic reprogramming.Furthermore, we evaluated the therapeutic efficacy of combined dexamethasone (DXM) and atorvastatin(AT) treatment, both in vitro and in an active ITP murine model.Methods Bone marrow (BM) samples were collected from 61 ITP patients and 46 healthy controls (HCs) at theDepartment of Hematology, Qilu Hospital of Shandong University, China. Additionally, LPC (16:0/0:0) induced the polarization of BMmacrophages toward M1 phenotype, while DXM reversed this shift, promoting M2 polarization.Conclusions Our study identifies LPC (16:0/0:0)-mediated metabolism-immunity crosstalk of macrophages as acentral pathogenic mechanism in ITP. We propose that the DXM–AT combination strategy may restoreimmune homeostasis by concurrently regulating metabolic and immune pathways."

Hematological Disorders • Immune Thrombocytopenic Purpura • Inflammation • Metabolic Disorders • Thrombocytopenia • Thrombocytopenic Purpura • CCR2 • CD68 • IL10

Injectable pentosan polysulfate: A novel cause of heparin-induced thrombocytopenia and stroke (ASH 2025) - "Aspirin and Atorvastatin were initiated, and Clopidogrel was deferred due to continuedthrombocytopenia.Due to the unusual presentation of ischemic stroke and isolated thrombocytopenia in a young femalewithout traditional risk factors, a comprehensive diagnostic evaluation was pursued. PPS was therefore identified as thelikely HIT trigger and the patient was treated with Argatroban and transitioned to Apixaban, with plateletcount recovery to 204x10³/μL.This case illustrates the importance of maintaining a broad differential when encountering unexplainedthrombocytopenia and thrombosis, as HIT may arise from unconventional exposures. Obtaining adetailed medication history, which includes unregulated and non-prescribed medications, is essential toidentifying a diagnosis."

Cardiovascular • Fatigue • Hematological Disorders • Immunology • Interstitial Cystitis • Ischemic stroke • Osteoarthritis • Rheumatology • Thrombocytopenia

A Multicenter, Prospective, Open-Label, Parallel Randomized Controlled Clinical Study on Atorvastatin Combined with Anti-Angiogenic Drugs for the Treatment of Liver Metastases from Colorectal Cancer (ChiCTR) - P=N/A | N=118 | Not yet recruiting | Sponsor: Shanghai Geriatric Medical Center; Shanghai Geriatric Medical Center

New trial • Colorectal Cancer • Oncology • Solid Tumor • APOB • KRAS • NRAS

Anthocephalus indicus and Terminalia arjuna Combination Ameliorates Hematological and Histopathological Changes in a Rat Model of Metabolic Syndrome. (PubMed, Cureus) - "The combined herbal formulation of A. indicus and T. arjuna demonstrated significant multiorgan protection in metabolic syndrome-induced rats. These findings suggest the potential of this phytotherapeutic approach as an effective alternative or adjunct in managing metabolic complications."

Journal • Preclinical • Diabetes • Hematological Disorders • Metabolic Disorders • Thrombocytosis

Effects of Catha edulis Extract on Atorvastatin-Induced Myotoxicity in Rats: Biochemical and Histopathological Evidence. (PubMed, J Exp Pharmacol) - "When combined with atorvastatin, these effects are exacerbated, leading to pronounced myopathy and kidney damage. These findings suggest that khat use may potentiate statin-induced rhabdomyolysis and increase the risk of musculoskeletal and renal complications."

Journal • Preclinical • Musculoskeletal Diseases • Myositis • MB

Risk of Hematuria, Proteinuria, and Cardiovascular Events in Patients Treated with Rosuvastatin Compared with Atorvastatin: A Retrospective Cohort Study in 136,680 Patients. (PubMed, Am J Cardiovasc Drugs) - "Compared with atorvastatin, rosuvastatin was associated with a significantly lower risk of cardiovascular events and a nonsignificant increase in hematuria and proteinuria. Overall, the cardiovascular benefits of rosuvastatin appear to outweigh the minor renal risks."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Nephrology • Renal Disease

A Delayed Diagnosis of Anti-HMG-CoA Reductase Immune-Mediated Necrotizing Myopathy (AHA 2025) - "Patient had been taking atorvastatin 40 mg daily for 3 years...Over the next 6 months while outpatient, the patient participated in physical therapy and completed two rituximab infusions with an oral steroid taper with only modest improvement in strength with 4/5 strength in upper proximal muscles and 3/5 in lower proximal muscles (Figure 1).DiscussionAnti-HMGCR IMNM is an autoimmune condition that is a rare complication of statin medications where there is painless progressive muscle strength loss despite statin discontinuation due to myofiber necrosis...Physicians should keep anti-HMGCR IMNM in the differential with a patient with suspected myopathy and on a statin, even if the statin was tolerated with no observable side effects for several years. Our case highlights a delayed diagnosis of anti-HMGCR IMNM requiring aggressive treatment with ultimately a modest clinical improvement and the risk of long-term debilitation without early detection."

Cardiovascular • Chronic Kidney Disease • Dermatomyositis • Dyslipidemia • Ischemic stroke • Myositis • Nephrology • Renal Disease

Non-invasive Hemodynamics for diabetic care with HEMOTAG (AHA 2025) - "Medication analysis revealed that drugs such as lisinopril (p = 0.0012), losartan (p = 0.0268), and atorvastatin (p = 0.0061) differed both in frequency and dosage between groups, implicating potential pharmacologic influences on CTI dynamics. This trend may suggest a potential association between abnormal CTI patterns and underlying coronary pathology, warranting further investigation in larger cohorts.ConclusionsAbnormal CTI patterns are associated with elevated cardiac biomarkers and distinct medication profiles. CTI analysis may offer a non-invasive, physiologically grounded tool for risk stratification and personalized cardiovascular therapy in diabetic patients."

Non-invasive • Cardiovascular • Diabetes • Metabolic Disorders

Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network (AHA 2025) - "This study compared the impact of statins versus ezetimibe on the vascular endothelium in patients receiving background PCSK9 inhibitor (PCSK9i) therapy. CHORD (CHOlesterol lowering and Residual Risk in Diabetes) is a prospective clinical study of LLT with the PCSK9i, Repatha 140mg, plus either atorvastatin 80mg (statin) or ezetimibe 10mg daily for 1 month to evaluate mechanisms of CV disease. We demonstrate that on a background of PCSK9 inhibitor therapy, statins provide greater improvements to EC health and anti-inflammatory effects, supporting their benefits beyond LDL-C reduction."

IO biomarker • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CD40 • CRP • IL23A • IL6 • MCAM

Left Ventricular Thrombus and Occluded Coronary Artery in a Patient with JAK2 V617F Mutation (AHA 2025) - "The patient was treated with apixaban, atorvastatin, and metoprolol. The presence of the JAK2 V617F mutation indicates an underlying prothrombotic condition, which may have increased the risk of hypercoagulation. Screening for JAK2 V617F mutation in patients with incidental LVT and totally occluded coronary arteries may deserve further investigation."

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Disorders • Myeloproliferative Neoplasm • Myocardial Infarction • Thrombosis • JAK2